Friday, April 19, 2019
Macrogenics is targeting B7-H3 with a Duocarmycin linked ADC
Macrogenics is working to use Duocarmycin along with the Synthon based linker conjugation technology to build ADCs targeting tumor vasculature.
Preclinical results have been positive as demonstrated at 2017 AACR.
If you can stem the growth of tumor vasculature can you cut off the nutrient supply of the tumor? Has this approach been effective with other treatments?